Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05928585 · ClinicalTrials.gov registry record · Phase 1
A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers
A Phase 1 study of Immune System Diseases and Autoimmunity, sponsored by HI-Bio, A Biogen Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05928585: Completed Phase 1 study of Immune System Diseases and Autoimmunity, sponsored by HI-Bio, A Biogen Company.
NCT05928585 is a Phase 1 study of Immune System Diseases and Autoimmunity that has completed, run by HI-Bio, A Biogen Company. The registered enrollment target is 30 participants, below the 151-participant average among 18 other Immune System Diseases trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05928585, a Phase 1 study of Immune System Diseases and Autoimmunity, has completed, sponsored by HI-Bio, A Biogen Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to test safety of the investigational product in healthy volunteers. The main questions it aims to answer is when HIB210 is administered as multiple doses, is it: 1. Safe 2. Well tolerated 3. Does the body absorb and eliminate HIB210 as expected
Conditions Studied
Interventions
- DRUG Placebo
- DRUG HIB210
Study Locations (1)
Florida
- HI-Bio Investigational Site - Hialeah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-07-06 |
| Est. Completion | 2024-06-10 |
| Phase | Phase 1 |
What the finished NCT05928585 record still lists
NCT05928585 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 151-participant average among 18 other Immune System Diseases trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Immune System Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05928585 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05928585 about?
NCT05928585 is a clinical study titled "A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers". The goal of this clinical trial is to test safety of the investigational product in healthy volunteers. The main questions it aims to answer is when HIB210 is administered as multiple doses, is it: 1. Safe 2. Well tolerated 3. Does the body absorb and eliminate HIB210 as expected
What is the current status of trial NCT05928585?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-07-06. Estimated completion is 2024-06-10.
What conditions does trial NCT05928585 study?
This clinical trial studies the following conditions: Immune System Diseases, Autoimmunity.
What interventions are being tested in trial NCT05928585?
The interventions under investigation include: Placebo (DRUG), HIB210 (DRUG).
Who is sponsoring clinical trial NCT05928585?
This trial is sponsored by HI-Bio, A Biogen Company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05928585 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune System Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05928585's enrollment target sits among peer trials
30 15th of 18 higher than 4 of 18 other Immune System Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Immune System Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
ACTIVE NOT RECRUITING · Phase 1
-
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
ACTIVE NOT RECRUITING · Phase 1
-
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
ACTIVE NOT RECRUITING · Phase 1
-
Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI